Please login to the form below

Not currently logged in
Email:
Password:

NICE remains against use of Tyverb, Herceptin for advanced form of breast cancer

New draft guidance says Roche and GSK still can't prove value for money of drugs for use on NHS

National Institute for Health and Clinical Excellence (NICE) has again declined to recommend Tyverb (lapatinib) and Herceptin (trastuzumab) for an advanced form of breast cancer.

The UK cost-effectiveness body's draft guidance said the ability of both GlaxoSmithKline's Tyverb and Roche's Herceptin to improve overall survival compared to existing treatments was uncertain and the drugs did not represent value for money on the NHS.

The guidance covers either drug's use alongside aromatase inhibitors as a first line treatment option to delay the growth of breast cancer that has spread to other parts of the body and where tumour cells react with the hormones oestrogen or progesterone and have high levels of a protein called HER2 on their surface.

NICE's latest draft guidance comes after an appeal from Roche against some of the committee's findings in the initial appraisal.

Although NICE chief executive Sir Andrew Dillon acknowledged that both Roche and GSK's drugs can reduce the growth and further spread of metastatic breast cancer tumours when taken alongside the aromatase inhibitors, the agency stuck with its initial negative decision.

Dillon said: [T]he extent that these treatments can improve overall survival appears to be small or undefined.”

In terms of drug costs, treatment with Tyverb using an oral dose of six 1500mg tablets per day plus aromatase inhibitor letrozole amounts to £28,212 for what NICE call a 'lifetime of treatment'.

Depending on the type of dose, a lifetime of treatment using Herceptin plus aromatase inhibitor anastrozole would cost either £26,018 or £26,832.

However, when converted to NICE's incremental cost effectiveness ratio (ICER), the most plausible cost per quality of life year (QALY) gained for Tyverb compared to using letrozole alone is £74,400, while the figure is over £51,000 for Herceptin compared to anastrozole alone. Both are well over NICE's £30,000 limit for QALY cost-effectiveness.

Herceptin is already recommended for use on the NHS in several indications, including for women who have early-stage HER2-positive breast cancer after they have had surgery and chemotherapy, as well as for HER2-positive metastatic gastric cancer. Tyverb is currently only recommended by NICE for use in clinical trials.

The latest draft guidance on the two drugs will be open for consultation, with comments accepted on NICE's website, until March 6, 2012.

14th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Reynolds-MacKenzie

Reynolds-MacKenzie is the multi award-winning specialist public relations practice within OPEN Health; the first ever agency in the health communications...

Latest intelligence

14_ipad_lowres.jpg
Do your customers feel that you’re listening to them?
When answering to data, excellent digital communication can create much stronger relationships between reps and customers....
Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...

Infographics